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Human papillomavirus (HPV) genome replication is dependent on the expression of E1 and E2 proteins. The organotypic
(raft) culture system was used to investigate changes in viral early gene expression and vegetative genome replication during
the complete life cycle of HPV type 31b (HPV31b). We have previously shown the synthesis of HPV31b viral particles as early
as 10 days of growth of CIN-612 9E raft tissues (Ozbun, M. A., and Meyers, C. (1997). J. Virol. 71, 5161–5172). In the present
study, we investigated the structures and temporal expression levels of HPV31b E1 and E2 transcripts, as well as the
replication of the viral genome during the viral life cycle. The amplification state of the HPV31b genome was maximal at 10
days of raft tissue growth. Furthermore, the expression levels of E1 and E2 RNAs correlated with vegetative viral DNA
replication. Levels of E1- and E2-specific transcripts were dissimilar throughout the viral life cycle. E2 RNA levels remained
relatively constant, whereas E1 RNA levels were upregulated during the maximal amplification of viral genomes and the
biosynthesis of virions. These data indicate that E1 may be the major regulator of viral genome amplification in preparation
for DNA packaging and virion morphogenesis. © 1998 Academic Press
INTRODUCTION
Human papillomaviruses (HPVs) are small DNA vi-
ruses that infect surface epithelia and cause both benign
and malignant lesions (Broker and Botchan, 1986; zur
Hausen, 1991). The subgroup of HPVs that produce le-
sions with a high probability of progression to malig-
nancy are termed high-risk viruses; HPVs that rarely
progress to invasive cancer are known as low-risk vi-
ruses. The high-risk HPV types that give rise to cervical
cancers include types 16, 18, 31, 33, and 45; HPV types 6
and 11 are examples of low-risk viruses (Lorincz et al.,
1992). The capacity of the viruses to cause tumors (or
warts) can be partially attributed to their ability to estab-
lish a persistent infection characterized by the mainte-
nance of episomal viral genomes in their host. However,
progression to malignancy is generally associated with
the integration of the viral genome into the host cell DNA
(Cullen et al., 1991).
The complete HPV replication cycle resulting in the
production of virions (i.e., infectious progeny) is tightly
linked to the differentiation state of the infected cells
(Taichman and LaPorta, 1987; Meyers et al., 1992, 1997).
According to a current model, the establishment of a
persistent papillomavirus infection occurs when the virus
enters a basal cell through a microabrasion in the epi-
thelial architecture (White et al., 1963; Broker and
Botchan, 1986). Viral persistence is set up through the
maintenance of extrachromosomal viral genomes at 50–
200 copies per infected cell on cellular division (Broker
and Botchan, 1986). During epithelial differentiation, HPV
genomes are amplified to levels of 1000–10,000 copies
per cell (Taichman and LaPorta, 1987; Bedell et al., 1991).
In the upper, differentiated layers of the epithelium, late
gene products are expressed, and together, late proteins
and amplified viral DNA (vDNA) presumably lead to the
morphogenesis of progeny virions (Meyers et al., 1992,
1997; Frattini et al., 1996).
The majority of data on papillomavirus genome repli-
cation are derived from transient assays using bovine
papillomavirus type 1 (BPV1) (reviewed by Lambert,
1991). A number of recent studies have shown that HPVs
share many of the BPV1 replication activities. The origin
of HPV DNA replication is located in the upstream reg-
ulatory region (URR) of viral genomes just 59 to the E6
open reading frame (ORF) (Del Vecchio et al., 1992).
Jointly, the HPV E1 and E2 viral gene products are nec-
essary for the replication of vDNA (Chiang et al., 1992;
Del Vecchio et al., 1992; Lu et al., 1993; Frattini and
Laimins, 1994b). HPV E1 is a nuclear phosphoprotein
that binds ATP and has DNA helicase activity (Bream et
al., 1993; Hughes and Romanos, 1993). The E1 protein
binds to a conserved A/T-rich sequence within the min-
imal origin of HPV DNA replication (Chiang et al., 1992;
Del Vecchio et al., 1992; Frattini and Laimins, 1994b). E2
is also a nuclear protein and can activate transcription by
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binding as a dimer to the E2 binding site (E2BS), a
conserved sequence of ACCGN4CGGT (Androphy et al.,
1987; McBride et al., 1989; Bream et al., 1993). Four
consensus E2BSs are located in the URR of HPV ge-
nomes; one E2BS lies just 39 to the A/T-rich E1 binding
site in the viral replication origin. HPV E2 complexes with
E1 and can stimulate E1-mediated replication (Bream et
al., 1993; Frattini and Laimins, 1994a; Frattini and
Laimins, 1994b). The affinity of E1 binding to the replica-
tion origin is increased by E2 proteins and requires an
adjacent E2BS (Frattini and Laimins, 1994a). In addition,
alterations in E1:E2 ratios affect the pattern of replication
factors binding to the viral origin in vitro (Frattini and
Laimins, 1994a). However, the mechanisms underlying
the regulation of E1 and E2 expression and vegetative
vDNA replication during the viral life cycle are poorly
understood.
To investigate the regulation of vDNA replication by
the E1 and E2 gene products, we used the organotypic,
or raft, culture system, which supports the complete HPV
life cycle (Meyers et al., 1992, 1997). Using the cervical
intraepithelial neoplasia (CIN)-612 9E cell line, which
maintains '50 copies of HPV31b per cell, we character-
ized transcripts potentially encoding the E1 and E2 pro-
teins. In addition, we correlated the expression of these
transcripts with the amplification of vDNA during the
process of epithelial differentiation and virion biosynthe-
sis in raft tissue cultures.
RESULTS
Temporal and spatial amplification of HPV31b DNA
during stratification of CIN-612 9E epithelium in the
organotypic culture system
The CIN-612 9E cell line in monolayer culture main-
tains the HPV31b genome episomally at an average of
'50 copies per cell (Bedell et al., 1991; Hummel et al.,
1992). To determine the onset and extent of HPV31b viral
DNA (vDNA) amplification in the raft tissue culture sys-
tem, CIN-612 9E epithelial cells were grown as raft tis-
sues as described in Materials and Methods. Because
protein kinase C (PKC) induction has been shown to
increase the differentiation of HPV-infected tissues in the
raft system (Meyers et al., 1992, 1997; Ozbun and Mey-
ers, 1996, 1997, 1998), the rafts were treated with the
synthetic diacylglycerol 1,2-dioctanoyl-sn-glycerol (C8:0)
every other day to induce the PKC pathway. Rafts were
harvested every second day for 16 days (days 2–16).
Total DNA was harvested from the raft tissues, digested
with restriction enzymes, and analyzed by agarose gel
electrophoresis and Southern (DNA) hybridization for
HPV31b vDNA. A comparison with DNA copy number
standards indicated that the 2-day rafts contained an
average of '200 copies of HPV31b DNA per cell (data
not shown). Viral DNA (vDNA) amplification continued to
increase at day 4, peaked at about day 10, and then
began to decrease (Fig. 1). The peak in vDNA at day 10
coincides with our previous data showing the presence
of intranuclear HPV31b viral particles as early as day 10
in CIN-612 9E raft tissues (Ozbun and Meyers, 1997). We
found it curious that the levels of vDNA declined after
day 10; however, these results were reproduced in at
least four separate experiments using similar extraction
conditions. We considered the possibility that as the rafts
continued to grow and stratify, they contained more cell
layers with a larger fraction of cells no longer supporting
vDNA replication. We reasoned that the analysis of DNA
from a set number of cells (i.e., a whole raft or a fraction
thereof) might alleviate problems with increasing cell
numbers during the stratification of the raft tissues. How-
ever, the amounts of total DNAs obtained from raft tis-
sues were remarkably equivalent from day 4 to day 16.
Thus, adjustment of the amounts of DNA analyzed by
Southern blotting accordingly did not significantly alter
the results compared with those shown in Figure 1.
To investigate the spatial and temporal vegetative rep-
lication of HPV genomes during the viral life cycle, in situ
hybridizations were performed on tissue sections of CIN-
612 9E rafts harvested at various time points. We previ-
ously reported that CIN-612 9E raft tissues reach maxi-
mal stratification and differentiation by day 12 in the
organotypic tissue culture system (Ozbun and Meyers,
1997). In situ hybridization for HPV31b vDNA in CIN-612
9E tissues harvested at day 4 gave moderate hybridiza-
tion signals in a few nuclei, whereas most nuclei showed
weak or no hybridization (Fig. 2E). As the raft tissues
continued stratification and differentiation to day 8, more
nuclei were found to show strong hybridization signals
with the HPV31 probe (Fig. 2F). Moreover, the strong
hybridization signals indicating amplification of HPV31b
genomes were observed throughout the tissue and in all
strata of the epithelia. By days 12 and 16, the CIN-612 9E
FIG. 1. Southern blot analysis of HPV31b genome amplification dur-
ing the viral life cycle. Cells were grown in raft cultures and PKC
induced with C8:0 treatment every second day, and rafts were har-
vested on the days indicated (d). Total cellular DNA corresponding to
106 cells (7.1 mg) was digested with BamHI, a noncutter in HPV31b. The
restriction enzyme-digested samples were separated by electrophore-
sis on a 0.8% agarose gel, transferred to a nylon membrane, and
hybridized with a 32P-labeled probed made from the complete HPV31
genome. Form I (FI) indicates supercoiled DNA, and form II (FII) points
to nicked circular DNA.
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tissues maintained strong HPV31 hybridization signals in
many nuclei (Figs. 2G and 2H). However, unlike the 8-day
raft tissues, which showed hybridization in most cells,
the 12- and 16-day raft tissues showed increasing areas
with no hybridization signal. To more effectively illustrate
that the number of cells supporting viral DNA amplifica-
tion diminished after 8 days, the total number of positive
cells within a defined, equivalent area of each cross
section was counted. Areas were counted on eight dif-
ferent sections of each time point, and the data are
presented in Table 1. Thus, the in situ hybridization data
are in agreement with the Southern blot hybridization
data showing an increase in vDNA content in the tissues
through day 10 in the raft system and then decreasing
levels of vDNA thereafter. In situ hybridization of the
HPV31 probe to CIN-612 9E monolayer cells gave weak-
to-moderate signals in most all of the nuclei (Fig. 2L).
Because Hummel et al. (1992) showed CIN-612 9E mono-
layers to contain an average of '50 copies of HPV31b
per cell, our data indicate that in situ hybridization dis-
plays a sensitivity of detecting ,50 copies of vDNA per
cell. Based on previous in situ analyses of 14-day raft
tissues of CIN-612 (Bedell et al., 1991), we estimate the
copy number of HPV31b genomes to be $103 in the
nuclei showing strong hybridization. Hybridizations of
HPV31 probes to sections of HCK18:1Bj raft tissues con-
taining episomal copies of HPV18 were negative, as
were sections of CIN-612 9E tissues and CIN-612 9E
monolayers hybridized with lambda DNA probes (Figs.
2B, 2C, and 2J, respectively). Hybridization of CIN-612 9E
tissues or monolayers with a probe made from total
CIN-612 9E DNA gave a strong signal in all nuclei (Figs.
2D and 2K, respectively), indicating that the probes had
access to all cells and throughout the strata of the raft
tissue. Pretreatment of the CIN-612 9E raft tissues with
RNase did not affect the level of hybridization with the
HPV31b probe observed in the nuclei (data not shown).
Conversely, pretreatment of the tissues with DNase abol-
ished the HPV31 hybridization in the CIN-612 9E nuclei
(data not shown). The latter two controls provide evi-
dence that the hybridization resulted from the presence
of vDNA rather than viral RNA.
Temporal expression of E1 and E2 transcripts in rafts
induced to differentiate and support the vegetative
life cycle of HPV31b
Because HPV E1 and E2 gene products are required
for the replication and stable maintenance of viral ge-
nomes (Ustav and Stenlund, 1991; Chiang et al., 1992; Del
Vecchio et al., 1992), we investigated the expression
levels of these transcripts during the viral life cycle. The
sizes and temporal levels of E1 and E2 transcripts were
analyzed by performing Northern (RNA) blot hybridiza-
tions on total RNAs harvested from untreated CIN-612 9E
monolayer cells and from PKC-induced CIN-612 9E rafts
harvested at 4, 8, 12, and 16 days after lifting to the
air–liquid interface. Probes specific to the ORFs of both
E1 and E2 identified mRNA species of '4.2 kb in all of
the samples (Fig. 3). This RNA species was found at high
levels in samples from CIN-612 9E monolayer cells, was
at lower levels in 4-day rafts, peaked in 12-day rafts, and
decreased in 16-day rafts. A transcript slightly smaller
FIG. 2. In situ hybridization of raft tissue sections or monolayer cells hybridized with fluorescein-labeled probes. Raft tissues were treated with 10
mM C8:0 every second day, whereas monolayer cells were untreated. (A) Hematoxylin and eosin staining of CIN-612 9E tissues harvested at day 8
showing the architecture of the raft tissue. (B–L) Tissues and cells counterstained with eosin Y. (B) HCK18:1Bj raft tissues containing episomal copies
of HPV18 grown for 12 days; hybridized with HPV31 probe. (C) CIN-612 9E tissues harvested at day 12; hybridized with lambda DNA probe. (D) CIN-612
9E raft tissues grown for 12 days; hybridized with total CIN-612 9E DNA probe. (E–H) CIN-612 9E raft tissues hybridized with HPV31 probe. Rafts were
harvested after (E) 4 days, (F) 8 days, (G) 12 days, and (H) 16 days. (J–L) CIN-612 9E monolayer cells hybridized with (J) lambda DNA probe, (K) total
CIN-612 9E DNA probe, and (L) HPV31 probe.
TABLE 1
Nuclei Positive for HPV31b by In Situ Hybridization
in CIN-612 9E Raft Tissues
Sample Averagea SD
4 day rafts 6.4 62.4
8 day rafts 15.8 63.6
12 day rafts 7.8 65.2
16 day rafts 7.4 66.4
a The numbers represent the average number of stained nuclei in
eight equivalently-sized cross sections.
FIG. 3. Northern analyses of HPV31b E1 and E2 transcripts. CIN-612
9E cells were cultured as monolayers (M; lane 1) or as raft tissues; the
rafts were treated with 10 mM C8:0 every second day. Rafts were
harvested after lifting to the air–liquid interface after 4 days (4d; lane 2),
8 days (8d; lane 3), 12 days (12d; lane 4), and 16 days (16d; lane 5). Ten
micrograms of each sample of DNase I-treated total RNA were ana-
lyzed. Probes were specific to either (A) the E1 ORF (HPV31b nt
1290–2400) or (B) the E2 ORF (HPV31 nt 2880–3279). Sizes of tran-
scripts were calculated by comparison with RNA markers (GIBCO BRL).
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than 4.2 kb was also observed in 12- and 16-day rafts
using both probes (Fig. 3, lanes 4 and 5). In addition to
the '4.2-kb transcript, the E2 probe detected a '2.4-kb
RNA species in all of the CIN-612 9E samples (Fig. 3B). In
the CIN-612 9E raft tissues, the '2.4-kb E2 RNA species
followed the same general expression pattern as did the
'4.2-kb E2 RNA species. The highest levels of the
'2.4-kb E2 ORF-containing RNAs were observed in CIN-
612 9E monolayer cells and in rafts harvested at day 12
(Fig. 3B, lanes 1 and 4, respectively). The E1-specific
probe also detected a transcript of '2.4 kb in rafts
harvested at 8, 12, and 16 days (Fig. 3A, lanes 3–5,
respectively) but not in monolayer cells or 4-day raft
tissues (Fig. 3A, lanes 1 and 2, respectively).
Cloning and sequencing of E1 and E2 gene
transcripts expressed during the HPV31b life cycle
The structures of the HPV31b early gene transcripts
were determined by RNA PCR amplification and se-
quence analysis. Total RNAs were extracted from CIN-
612 9E monolayers and rafts, were treated with DNase I,
and were subjected to RNA PCR using primers specific
for the early region of HPV31b (Fig. 4). After PCR ampli-
fication, cDNA products were cloned and sequenced.
Three novel cDNAs corresponding to spliced transcripts
containing the early gene ORFs of HPV31b were identi-
fied; one product corresponding to an unspliced tran-
script was observed. The use of primers E6 59 and E1 39
FIG. 4. cDNA-derived HPV31b sequences from PKC-induced CIN-612 9E tissues. Total or poly(A)1 RNA was extracted from CIN-612 9E raft
tissues at day 12 and monolayer cultures. RNA (1 mg) was subjected to reverse transcription, and the cDNAs were amplified by PCR with the
primer pairs indicated (Table 1). (Top) Results of dideoxy sequencing of cloned PCR-amplified cDNA products. Below the sequence data is a
schematic of the HPV31b genome arbitrarily linearized following the late polyadenylation signal (A1). HPV31b nt numbering is based on the
sequence of HPV31 (Goldsborough et al. (1989). The major ORFs are shown as open boxes, and the upstream regulatory region (URR) is
denoted. Bent arrows indicate the constitutively expressed promoters P77, P99, and P3320 and the differentiation-specific promoter P742 (Hummel
et al., 1992; Ozbun and Meyers, 1998). The early and late polyadenylation sites (A1) at nt 4138–4143 and 7227–7231, respectively, are shown.
Restriction sites important for cloning (HincII at nt 1003) and for genome linearization (XbaI at nt 4998) are given. Placement of oligonucleotide
primers used for PCR analyses are shown by arrows. (A–D) The transcripts are predicted to initiate at both P77 and P99 promoters (Ozbun and
Meyers, 1998) and to end at the early poly(A)1 site (A1). The thin, dotted lines mark regions removed by splicing; open and stippled boxes
represent ORFs; and thick lines are noncoding regions. (Right) The ORF coding potential of the transcript. (A) RNA PCR using primers E6 59
and E1 39 gave a 595-bp partial cDNA containing the 36* splice and the E1*I splice (top). The construct containing this cDNA was designated
pCR31b-E69E. (B) Primers E6 59 and E1 39 gave rise to an RNA-PCR product of '800 bp corresponding to a partial cDNA containing
E6,E7,E1*I,E2 ORFs. (C) RNA PCR using primers E6 59 and E1–2 39 resulted in a 2080-bp partial cDNA containing the ORFs E6* and E7 and
the 59 region of E1. The construct containing this cDNA was designated pCR31b-E6E1.2b. (D) Primers E6 59 and E1–2 39 gave an RNA PCR
product of '2300 bp corresponding to a partial cDNA containing the unspliced E6,E7,E1 ORFs.
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resulted in the amplification of a product of 595 bp (Fig.
4A). Sequencing revealed this partial cDNA to be made
up of the E6* ORF, the E7 ORF, and a splice from the E1
donor at nucleotides (nt) 877 to nt 2646 upstream of the
E2 start codon at nt 2693. The latter splice results in the
truncation of the E1 ORF to a 10-amino-acid fusion pep-
tide designated E1*I. We recently reported the structure
of this transcript as one that initiates from the P77 pro-
moter (Ozbun and Meyers, 1998). RNA PCR amplification
on total and polyadenylation-selected [poly(A)1] RNA
preparations from CIN-612 9E cells reproducibly resulted
in a product of '800 bp corresponding in size to tran-
script B in Figure 4, a potential transcript containing the
ORFs of E6,E7,E1*I. RNA PCR amplification using the
same primers on total and poly(A)1 RNA preparations
from the HPV-negative epithelial raft tissues of SCC-13
cells yielded no products (data not shown). Transcripts A
and B (Fig. 4) are predicted to initiate at either or both of
the P77 and P99 promoters (Ozbun and Meyers, 1998).
Continuation of these spliced RNAs through to the
HPV31b early poly(A)1 site at nt 4138–4143 would yield
transcripts '2.4 kb in length depending on the extent of
mRNA polyadenylation. This is in agreement with the
Northern blot analyses showing an E2 ORF-specific tran-
script of '2.4 kb (Fig. 3B). The use of primers E6 59 and
E1–2 39 resulted in the amplification of a product of 2080
bp (Fig. 4C). Sequencing revealed this partial cDNA to
contain the ORFs of E6*, E7, and the 59 region of E1.
RNA-PCR amplification using either total or poly(A)1 RNA
preparations from CIN-612 9E cells reproducibly yielded
a product corresponding in size to transcript D in Figure
4. This transcript is predicted to contain the E6,E7,E1
ORFs. Because this product is predicted not to contain
any spliced sequences, we cannot rule out that amplifi-
cation was from contaminating vDNA and not from viral
RNA. Again, RNA PCR amplification using primers E6 59
and E1–2 39 on total and poly(A)1 RNA preparations from
SCC-13 cells failed to yield products of similar sizes (data
not shown). Viral RNAs depicted in Figures 4C and 4D
are also predicted to initiate at either or both of the P77
and P99 promoters (Ozbun and Meyers, 1998), and con-
tinuation through to the early poly(A)1 site would yield
polyadenylated transcripts of '4.2 kb. These RNAs
would also contain the E2 ORF, and the data concur with
the Northern blot analyses showing E1 and E2 ORF-
specific transcripts of '4.2 kb (Fig. 3). Using the primer
E1 59 and various downstream primers shown in Figure
4, we found no evidence for additional E1 ORF-contain-
ing transcripts that might correspond to the '2.4-kb E1
transcript detected by Northern blot analysis (Fig. 3A).
Quantification of E1 and E2 RNAs expressed during
the viral life cycle
To quantify the relative changes in temporal E1 and E2
mRNA expression among CIN-612 9E untreated mono-
layer cultures and PKC-induced rafts harvested at vari-
ous time points, samples were analyzed by ribonuclease
(RNase) protection assays (RPAs) using antisense RNA
probes specific to internal regions of the E1 and E2 ORFs
(Fig. 5C). The E1-specific riboprobe protected the ex-
pected 337-nt fragment of RNA (Fig. 5A), whereas the
E2-specific riboprobe protected a 260-nt fragment, as
predicted (Fig. 5B). For both probes, the RPAs gave pat-
terns of temporal RNA levels consistent with the results
of the Northern analyses. Monolayer cultures of CIN-612
9E cells were found to express both E1 and E2 RNAs
(Figs. 5A and 5B, lane 1). Furthermore, E1 and E2 tran-
script levels peaked at day 12 in PKC-induced CIN-612
9E rafts (Figs. 5A and 5B, lane 4). The relative changes in
the levels of the E1 and E2 transcripts were determined
by densitometric scanning (Fig. 5D). The results indi-
cated that the levels of E1 and E2 RNAs were similar in
undifferentiated monolayer cells and in partially differen-
tiated 4-day raft tissues. However, E1 transcripts showed
a stronger peak in expression over that of the E2 RNAs
at 12 days in differentiating raft tissues supporting the
HPV31b life cycle. These RPA data were representative
of several analyses. The bands of '200 and '120 nt
seen in the sample lanes appeared to be due to E1 probe
degradation because they were visible in the probe lane
on longer exposure of the gel (Fig. 5A).
RPAs using cDNA-derived probes were performed to
determine the temporal expression pattern of specific
spliced viral mRNAs during PKC-induced differentiation of
the raft epithelial tissues. Total RNAs from PKC-induced
rafts were harvested at intervals after lifting to the air–liquid
interface; representative results of multiple experiments are
shown in Fig. 6. The cDNA clones obtained from RNA PCR
and illustrated in Figures 4A and 4C served as templates
for antisense RNA probes for RPAs. The results verified that
the temporal expression patterns of the spliced E1 and E2
RNA species were similar to the results obtained by North-
ern analysis (Fig. 3) and to the results obtained by RPA
using probes internal to the E1 and E2 ORFs (Fig. 5). The
antisense riboprobe of 705 nt made from the E6*,E7,E1
template (Fig. 6C) had the potential to detect and quantify
both species of E1 ORF-containing transcripts shown in
Figure 4 (transcripts C and D). Specific protection of the
E6*,E7,E1 transcript showed a protection of a 682-nt frag-
ment as expected (Fig. 6A). This indicated that the
E6*,E7,E1 transcript was expressed in a temporal fashion
similar to that observed by Northern and internal RPA anal-
yses (Figs. 3A and 5A, respectively). The protection of an
unspliced E6,E7,E1 transcript by the same probe was ex-
pected to be 591 nt in length. However, no protection of this
size was seen, indicating that the E6,E7,E1 RNA species
was not a major constituent of E1 ORF-containing tran-
scripts (Fig. 6A). As expected, the E6*,E7,E1 riboprobe de-
tected two versions of transcripts using the E1 splice donor:
E6*,E7,E1^ and E6,E7,E1^ (Fig. 6A). These sequences are
present on the 59 ends of many spliced HPV31b transcripts,
223HPV31B DNA REPLICATION CORRELATES WITH E1/E2 RNA LEVELS
including those containing the E2 ORF (Figs. 4A and 4B)
(Ozbun and Meyers, 1998), those containing the E1^E4
fusion ORF (Hummel et al., 1992; Ozbun and Meyers, 1997),
and numerous late gene RNAs (Ozbun and Meyers, 1997).
Thus, it is not surprising that these protected fragments
were detected in greater quantities than the E6*,E7,E1 tran-
scripts. An E7,E1*I,E2 antisense riboprobe of 276 nt (Fig. 6C)
was created to detect and quantify the spliced species of
E2 ORF-containing transcripts shown in Figure 4 (tran-
scripts A and B). Specific protection of the E7,E1*I,E2 tran-
script produced a 169-nt protection as expected (Fig. 6B).
Temporal expression followed the same pattern observed
for E2 transcripts by Northern analysis (Fig. 3B) and by
internal E2 ORF RPA (Fig. 5B). As anticipated, strong 131-nt
protections corresponding to transcripts containing E7,E1^
were observed. Densitometry scanning of the protected
fragments of the spliced E1 and E2 transcripts gave results
similar to those obtained from the internal E1- and E2-ORF
RPAs shown in Figure 5D (data not shown).
HPV types 6 and 11 use a differentiation-dependent
promoter in the E7 ORF to initiate a subset of E1 ORF-
containing transcripts (Chow et al., 1987; DiLorenzo and
Steinberg, 1995). The analogous promoter in HPV31b is
P742 (Hummel et al., 1992; Ozbun and Meyers, 1997).
Using primer E1–4 39 (Table 1, Fig. 4) in primer extension
assays, we detected a minor population of E1-specific
transcripts initiating at P742 in RNA samples from differ-
entiating raft tissues but not RNAs from monolayer cells
(data not shown). Nuclease S1 and exonuclease VII
protection assays confirmed these observations but
showed that .90% of the E1 RNAs initiated at the P77/P99
promoters (data not shown). An E1 transcript initiating at
P742 and continuing through the E1 ORF to the early
poly(A)1 site would be predicted to be '3.4 kb in length.
E1 and E2 RNAs of this approximate size can be seen
below the arrow, indicating the 4.2-kb transcripts in the
Northern blot samples of 12- and 16-day rafts (Figs. 3A
and 3B, lanes 4 and 5, respectively). Primer extension
analyses using primers E7 39, E1–4 39, and E4 39 (Table
1, Fig. 4) suggested the presence of a 59 RNA end at
HPV31b nt 834. However, nuclease protection assays
using RNases, nuclease S1, and exonuclease VII pro-
vided no supportive data for an RNA start site in this area
(data not shown).
Correlation of E1 and E2 transcript levels with vDNA
amplification
The increase in E1 and E2 mRNA synthesis between 8
and 12 days coincided with the peak in vDNA amplifica-
FIG. 5. Ribonuclease protection analyses quantifying HPV31b E1 and E2 transcripts. CIN-612 9E cells were cultured as monolayers (M; lane 1) or
as rafts treated with 10 mM C8:0 every second day. Rafts were harvested after lifting to the air–liquid interface after 4 days (4d; lane 2), 8 days (8d;
lane 3), 12 days (12d; lane 4), and 16 days (16d; lane 5). Ten micrograms of DNase I-treated total RNA or yeast RNA (Y) were analyzed. Two yeast
RNA samples were included as controls; the yeast RNA samples in lane 6 were RNase digested to show probe specificity, and the yeast RNAs in
lane 7 were not RNase digested to indicate the size of the input probes. (Left) Sizes of the probes and predicted sizes of the protected fragments.
(Right) Placement of RNA Century Markers (Ambion). (A) Probe is specific to the E1 ORF (HPV31 nt 2064–2400). (B) Probe is specific to the E2 ORF
(HPV31 nt 3020–3279). (C) Schematic of HPV31b early region with riboprobes illustrated. (D) Densitometric data from A and B; autoradiograms were
scanned in the regions containing the full-length protected fragments. Absolute readings were plotted and represent the relative changes during
epithelial stratification and differentiation. M, E1 RNA levels. F, E2 RNA levels.
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tion in the differentiating raft tissues (Fig. 1). The corre-
lation between E1 and E2 transcript levels and vDNA
amplification during the viral life cycle was investigated.
The data were compared from densitometry scanning of
the autoradiogram of a Southern blot of linearized vDNA
from rafts harvested at various time points (as in Fig. 1;
data not shown) and from the autoradiograms of the
quantitative RPAs shown in Figures 5 and 6. As the ratio
of E1 transcripts to E2 RNAs increased, vDNA was found
to be amplified (Fig. 7). The ratio of E1 to E2 transcripts
was greatest between days 8 and 12, corresponding to
the peak in vDNA replication observed at day 10 in the
raft tissues.
DISCUSSION
We investigated the amplification of HPV31b vDNA
and characterized the structures and temporal expres-
sion patterns of E1 and E2 transcripts during the com-
plete viral life cycle using the organotypic (raft) tissue
culture system. We found the raft tissue culture system
faithfully mimics important morphological and biochem-
ical aspects of epithelial differentiation (Ozbun and Mey-
ers, 1996, 1997) and references therein). Our careful
optimization and maintenance of tissue growth in the raft
system result in reproducible histological and quantita-
tive molecular data. Moreover, we are consistently able
to purify high levels of total RNA from 4–16-day rafts
('100 mg/raft). PKC-induced CIN-612 9E tissues undergo
a program of stratification and differentiation by day 12 in
the raft system, morphologically resembling the in vivo
tissue from which the cells were originally derived
(Ozbun and Meyers, 1997). Furthermore, by day 12, the
CIN-612 9E raft tissues are fully able to support the
complete HPV life cycle as assayed by the ability to
detect vDNA amplification, late gene transcripts, capsid
proteins, and viral particles (Bedell et al., 1991; Meyers et
al., 1992; Ozbun and Meyers, 1997, 1998). Using a cell
line that maintains episomal copies of HPV18, we re-
cently demonstrated the purification of infectious viral
particles from raft tissues harvested at day 12 (Meyers et
al., 1997). We analyzed monolayer cultures in parallel
with raft tissues as a point of reference. However, our
previous analyses of temporal raft epithelial differentia-
tion and HPV31b late gene transcripts indicated that
monolayer cells are not analogous to basal cells either
morphologically or biochemically (Ozbun and Meyers,
1997). In addition, we point out that 2–4-day raft tissues
with their dermal equivalent (i.e., the fibroblast–collagen
matrix) and three-dimensional growth are structurally
and morphologically akin to basal cells. This is the first
investigation of temporal HPV genome amplification and
E1 and E2 transcript expression during the differentia-
tion-dependent viral life cycle. We report that amplifica-
tion of vDNA peaks near day 10 as the ratio of E1 to E2
transcripts is greatest during the in vitro propagation of
HPV31b.
PKC-induced CIN-612 9E raft tissues were analyzed at
various times during growth in the raft system. Initially,
we found it surprising that vDNA levels increased up to
days 10–12 and then began to drop. We expected the
genome levels to either keep increasing from day 2 to
day 16 or to peak and remain constant as viral particles
assembled and accumulated in the keratinized tissues.
We increased the detergent or reducing agent concen-
trations, or both, in the DNA extraction buffer with the
goal of releasing vDNA from particles potentially trapped
in the keratin bundles of the suprabasal cells. However,
this approach failed to yield an increase in vDNA extrac-
tion (data not shown). In situ hybridization was used to
FIG. 6. Ribonuclease protection assays quantifying spliced HPV31b
E1 and E2 transcripts. CIN-612 9E cells were cultured as monolayers
(M; lane 1) or as raft tissues treated with 10 mM C8:0 every second day.
Rafts were harvested after lifting to the air–liquid interface after 4 days
(4d; lane 2), 8 days (8d; lane 3), 12 days (12d; lane 4), and 16 days (16d;
lane 5). Ten micrograms of total RNA or yeast RNA (Y) were analyzed.
Yeast RNA controls included RNase digestion to show probe specificity
(lane 6) and yeast RNAs not RNase digested to indicate the size of the
input probes (lane 7). (Left) Sizes of the probes and sizes of the
protected fragments. (Right) Placement of RNA Century Markers (Am-
bion). (A) Probe is derived from HPV31b cDNA clone pCR31b-E6*E1
and is specific to 682 nt of E6*,E7,E1 (HPV31 nt 120–210^413–1003), 556
nt of E6*,E7,E1 (HPV31 nt 120–210^413–877), and 465 nt of E6,E7,E1
(HPV31 nt 413–877). (B) Probe is derived from HPV31b cDNA clone
pCR31b-E7 9E and is specific to 169 nt of E7,E1*I,E2 (HPV31 nt 747–
877^2646–2683) and 131 nt of E7,E1 (HPV31 nt 747–877). (C) Schematic
of the early region of HPV31b illustrating the placement of riboprobe
sequences.
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analyze the levels of HPV31b genomes in CIN-612 9E
monolayers and raft tissues. The copy number average
of '50 genomes per cell was readily detected in mono-
layer cells. Spatial analysis by in situ hybridization indi-
cated that nearly every nuclei gave evidence of vDNA
amplification in CIN-612 9E 8-day raft tissues. Con-
versely, raft tissues harvested after 8 days showed in-
creasing areas of cells that lacked vDNA amplification in
their nuclei, with many nuclei showing no evidence of the
basal number of '50 copies per cell. The focal amplifi-
cation of vDNA in certain cells with other groups of cells
showing no vDNA was also observed in 14-day rafts from
another clonal cell line containing episomal copies of
HPV31b (CIN-612–5) (Bedell et al., 1991). These investi-
gators suggested that there might be preferred regions
of viral amplification. Our data showing amplification of
vDNA in most nuclei of CIN-612 9E raft tissues at day 8
suggests that the high levels of vDNA once present in
most cells are lost, suppressed, or otherwise inaccessi-
ble to the techniques used. The phenomenon of decreas-
ing HPV activities in raft tissues after days 8–12 seems to
be a general one, as we also have observed decreased
levels of early gene transcripts (present report), late gene
transcripts (Ozbun and Meyers, 1997), and expression
from viral promoters (Ozbun and Meyers, 1998). Thus,
our findings suggest the general decrease in vDNA am-
plification in the raft tissues after day 10 may be a
function of gradual and subtle viral breakdown in the raft
system and not necessarily one of viral mandate. There
appears to be some dependence of vDNA amplification
on cellular differentiation as monolayer and 4-day raft
tissues do not fully support vDNA amplification (present
study; Bedell et al., 1991). Nonetheless, we and others
have shown that undifferentiated basal epithelial cells
support vDNA amplification (present study; Bedell et al.,
1991; Frattini et al., 1996)), indicating that vegetative viral
DNA amplification is not completely differentiation de-
pendent. Although there are clinical lesions that show no
detectable HPV vDNA in the basal or lower suprabasal
cells, there are also cases in which HPV vDNA was
readily detected in these lower strata and throughout the
epithelial strata (Grubendorf and zur Hausen, 1979; Koss,
1987; Schneider et al., 1987; Vallejos et al., 1987; Tase et
al., 1989; Cooper et al., 1991). Therefore, it appears more
likely that virion assembly is differentiation dependent
because the viral genomes are packaged by late pro-
teins, which are expressed only in the differentiated
suprabasal layers of the epithelium (Meyers et al., 1992;
Frattini et al., 1996).
Levels of both E1 and E2 transcripts were maximally
expressed at day 12 in the raft tissues, albeit the E1
RNAs were induced to a greater extent than the E2
RNAs. These analyses give no information on the spatial
expression patterns of E1 and E2 RNAs throughout the
epidermal tissues. However, in situ hybridization tech-
niques localized HPV11 E1 and E2 transcripts to the
nuclei of basal and suprabasal cells with a greater con-
centration of the RNAs in the upper, differentiated layers
of the epithelium (Stoler et al., 1989; Dollard et al., 1992).
Furthermore, HPV11 E1 transcript levels by in situ hybrid-
ization appeared to be higher than E2 RNA levels in raft
tissues (Dollard et al., 1992).
Structural analyses of the high-risk HPV31b transcripts
provided a number of similarities as well as many differ-
ences with low-risk HPVs. We detected four transcripts
with the potential of encoding the E2 ORF and two
transcripts containing the E1 ORF. The HPV31b tran-
scripts illustrated in Figure 4 are structurally similar to
HPV11 E1 and E2 ORF-containing transcripts (Chow et
al., 1987; Rotenberg et al., 1989), with a distinction being
that low-risk HPV types do not use a splice within the E6
ORF that yields the E6* ORF (Smotkin et al., 1989). We
found no evidence for splice junctions analogous to
those reported in the HPV11 E1M^E2C or E1M,E2C tran-
scripts (Chiang et al., 1991). Based on RNA PCR and
Northern blot analyses, we conclude that the HPV31b
transcripts initiate at the P77 or P99 promoters, or both,
and are polyadenylated at the early poly(A)1 site (Ozbun
and Meyers, 1998). Low-risk HPVs use a differentiation-
dependent promoter in the E7 ORF to initiate a subset of
E1 ORF-containing transcripts (Chow et al., 1987;
DiLorenzo and Steinberg, 1995). However, we found only
a very minor subset (,10%) of HPV31b E1 ORF-contain-
FIG. 7. Densitometric data comparing the ratio of E1 to E2 RNA levels
with the amplification of vDNA during the HPV31b life cycle. Autora-
diograms of RNase protection assays and Southern blot hybridizations
were scanned, and the absolute readings were plotted vs days of
tissue growth in the raft system. Striped boxes represent the ratio of E1
to E2 RNA levels from Figure 5D, and lines represent levels of vDNA
obtained from a Southern blot using an HPV31 probe (see Fig. 1). The
total DNA samples were digested with XbaI to linearize the HPV31b
genome for quantitative purposes.
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ing RNAs initiated at the differentiation-dependent P742
promoter.
The polycistronic nature of HPV transcripts dictates
that translation of E1 and E2 ORFs would occur by
internal ribosome initiation. The E1 ORF contains a
strong ribosome consensus sequence, suggesting ef-
ficient internal initiation (Kozak, 1991). Quantitative
RNase protection assays failed to detect transcripts
corresponding to E6,E7,E1 in CIN-612 9E monolayers
or raft tissues, suggesting that E1 proteins are synthe-
sized primarily from E6*,E7,E1 transcripts. The E1
probe recognized a '2.4-kb transcript by Northern
analysis in the raft tissues but not in the monolayers,
whereas the E2 probe recognized a '2.4-kb transcript
in both the raft tissues and the monolayers. Because
the E1 probe failed to recognize this '2.4-kb transcript
in the monolayers and because the '2.4-kb E2 tran-
scripts (E6,E7,E1*I,E2 and E6*,E7,E1*I,E2) do not con-
tain any of the sequences recognized by the E1 probe,
we do not believe these to be the same transcript
species. However, we characterized no cDNAs that
might account for such an E1 transcript. This '2.4-kb
RNA species likely contributes substantially to the
increase in total E1 ORF-containing transcripts found
in the differentiating raft tissues and also may be
important for E1 protein synthesis. The short E1*I ORF
terminates 30 bp upstream of a good translational
consensus sequence preceding the E2 ORF. Analyses
of HPV11 transcripts indicated that functional E2 pro-
teins were efficiently synthesized from E6,E7,E1*I,E2
(also called E6,E7,E2) but not from E6,E7,E1,E2 RNAs in
which the E1 ORF overlaps the E2 start codon (Roten-
berg et al., 1989).
In this study, we found that maximal vDNA amplifica-
tion in the raft system occurred when the ratio of E1 to E2
transcripts was increased by '3:1. Sverdrup and Khan
(1994) showed that optimal replication of HPV18 origins
occurred at a 5–10:1 ratio of E1 to E2 expression plas-
mids using transient assays. These data do not address
the issue of E1 and E2 protein levels in the cells. How-
ever, results from footprinting assays on the minimal
HPV31b replication origin indicate that E1 binds to nt
7905–24, a region with a 10-bp inverted repeat 59 to a
high-affinity E2BS at nt 38–49 (Frattini and Laimins,
1994b). The size of the E1-protected region suggests that
multiple E1 proteins might bind as a complex to the
sequence, whereas E1/E2 complexes bind to E2BSs
(Frattini and Laimins, 1994b,1994a). In addition, transfec-
tion of E1 expression vectors into CIN-612 9E monolayer
cells (which we showed to contain similar levels of E1
and E2 RNAs; see Fig. 5D) was found to increase viral
genomic copy number '3-fold (Frattini and Laimins,
1994a). Together, these findings are in accord with a
model in which vegetative HPV vDNA amplification oc-
curs as the protein ratio of E1 increases over that of E2
during the later stages of the viral life cycle. Interestingly,
it was recently demonstrated that there is a switch from
the semiconservative theta structure mode of HPV16
viral genome replication to the rolling circle mode of viral
replication during epithelial differentiation of W12-E cells
in the raft system (Flores and Lambert, 1997). It is tempt-
ing to speculate that the increased ratio of E1 to E2
proteins may contribute to this mechanistic switch.
MATERIALS AND METHODS
Cell and rat tissue culture
The CIN-612 9E cell line is a clonal line established
from a cervical intraepithelial neoplasia grade I biopsy
(Bedell et al., 1991) that maintains '50 episomal copies
of HPV31b per cell (Hummel et al., 1992). The HCK18.1Bj
cell line is a clonal line that maintains episomal copies of
HPV18 at '100 copies per cell (Meyers et al., 1997). The
SCC-13 cell line was established from a squamous cell
carcinoma of the facial epidermis and is HPV negative
(Rheinwald and Beckett, 1981). Epithelial cells were cul-
tured in E medium with mitomycin C-treated murine J2
3T3 fibroblast feeder cells (Meyers, 1996). Organotypic
(raft) tissue cultures for in vitro differentiation were main-
tained as previously described (Meyers, 1996; Ozbun
and Meyers, 1996, 1997). Epithelial cells were seeded
onto collagen matrices containing J2 3T3 fibroblasts sub-
merged under E medium. When the epithelial cells had
grown to confluence, the media were removed, and the
collagen matrices were lifted onto stainless steel grids.
Subsequent feeding of the epithelium was via diffusion
of E medium from below the matrix. Epithelial tissues
were allowed to stratify and differentiate at the air–liquid
interface over a 16-day period. Rafts were treated with 10
mM 1,2-dioctanoyl-sn-glycerol (C8:0; Sigma Chemical
Co., St. Louis, Missouri) in E medium every other day.
Raft tissues were harvested at various time points be-
ginning with the second day after being lifted to the
air–liquid interface (day 2) and extending to day 16 after
being lifted.
Nucleic acid extractions
Total cellular DNA was harvested by incubating raft
tissues for 3 h at 55°C in 10 mM Tris–Cl, pH 7.5, 25 mM
EDTA, 0.2% SDS, 100 mg/ml proteinase K, and 50 mg/ml
RNase A. The DNAs were sheared by passage 10 times
through an 18-gauge needle. The solution was extracted
twice with an equal volume of phenol–chloroform–
isoamyl alcohol (25:24:1) and then extracted once with
an equal volume of chloroform–isoamyl alcohol (24:1).
The DNAs were ethanol precipitated using 0.3 M sodium
acetate. Total RNAs were extracted from rafts, and mono-
layer cells were extracted with TRIzol Reagent (GIBCO
BRL, Bethesda, Maryland). RNA samples were treated
with deoxyribonuclease (DNase) I to remove copurifying
viral and cellular DNA (Ozbun and Meyers, 1997, 1998).
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RNA concentrations were based on optical densities;
concentrations were verified by electrophoresis through
agarose gels and staining with ethidium bromide.
Southern (DNA) and Northern (RNA) blotting and
hybridization
Total cellular DNA samples (5 mg) were either di-
gested with BamHI, which does not cut in the HPV31b
genome, or with XbaI, which linearizes the HPV31b ge-
nome at nt 4998. Total cellular DNA samples were sep-
arated on 0.8% agarose gels; total RNA samples (20 mg)
were separated on 1% agarose–0.66 M formaldehyde
gels as described (Ausubel et al., 1995). The nucleic
acids were transferred to GeneScreen Plus membranes
(New England Nuclear Research Products, Boston, Mas-
sachusetts), which were handled according to the man-
ufacturer’s instructions. pBS-HPV31 was digested with
EcoRI to release the complete HPV31 genome, and the
HPV31 sequences were purified from plasmid se-
quences by agarose gel electrophoresis and gene clean-
ing (Bio101, Vista, California). The E1 ORF probe was
made from plasmid pCR31b-E1 (see below) and includes
HPV31b nt 1290–2400. The E2 ORF-specific probe was
synthesized from pCR31-E2 and contains HPV31 nt
2880–3279. The radioactive labeling of DNA sequences
and the hybridizations were carried out as previously
described (Ozbun and Meyers, 1997). Membranes were
washed to remove nonspecific hybridization and then
exposed to Reflection film with intensifying screens (Du-
Pont NEN).
In situ hybridizations
Harvested rafts were fixed in 10% buffered Formalin
and embedded in paraffin, and 4-mm cross sections
were prepared. Thin sections on slides were incubated
at 55°C for 1 h followed by two 3-min rinses in xylene to
remove residual paraffin. The sections were rehydrated
in graded ethanol and then incubated in phosphate-
buffered saline (PBS). Monolayer cells were grown in
slide chambers, and subconfluent cells were fixed in 10%
buffered Formalin for 10 min; the slides were subse-
quently processed identically to the tissue sections. The
tissues were denatured in 0.02 M HCl for 10 min, rinsed
in 0.01% Triton X-100 in PBS for 90 s, and washed twice
in PBS for 3 min each. The sections were digested with
100 mg/ml of proteinase K in TE buffer for 10 min at 37°C
and then neutralized in a solution of 2 mg/ml glycine in
PBS for 5 min. Control sections were pretreated with
either 550 units/ml of RNase-free DNase I or 10 mg/ml
RNase A. The slides were washed in cold 20% acetic
acid for 15 s and then allowed to air dry for 15 min.
Fluorescein-labeled probes were synthesized, and in
situ hybridizations were performed using the DNA color
kit (Amersham Life Sciences, Buckinghamshire, UK) with
minor modifications. Probes of HPV31, HindIII-digested
lambda DNA, or total CIN-612 9E DNA were mixed with
hybridization buffer, and 40-ml aliquots were applied over
the tissue sections. The probe solutions and sections
were covered with polyethylene coverslips and were
denatured on a dry block surface at 100°C for 10 min.
The samples were incubated in a humidified box at 42°C
for 16–20 h. Stringency washes and detection of specific
hybridizations were performed as recommended by the
manufacturer. The tissue sections were counterstained
with eosin Y and visualized by light microscopy.
RNA PCR analyses, cloning, and sequencing
DNase I-treated total RNAs were reverse transcribed
using oligo(dT)16 or random hexamer primers, and PCR
was performed using the GeneAmp RNA PCR kit ac-
cording to the manufacturer’s directions (Perkin–
Elmer, Branchburg, New Jersey). All PCR primers (Ta-
ble 1) were synthesized by Operon Technologies (San
Diego, California) and were used at 0.5 mM. The ther-
mocycling profile was as follows: 4-min time delay at
94°C; 35 cycles including 94°C for 30 s, 58–60°C for 1
min, and 72°C for 2 min; and a 15-min extension at
72°C. PCR products were cloned using the TA cloning
kit (InVitrogen, San Diego, California). pCR31b-E1 con-
tains a 1111-bp fragment of the HPV31b E1 ORF gen-
erated by PCR using primers E1–2 59 and E1–2 39 on
cDNA sequences from CIN-612 9E raft tissues.
pCR31-E2 is the result of cloning the 400-bp PCR
product from the E2 ORF of plasmid pBR-HPV31 using
primers E2 59 and E2 39. pCR31b-E69E was produced
by cloning of the 595-bp PCR product generated with
primers E6 59 and E1 39 on cDNA from CIN-612 9E raft
tissues, and it contains HPV31b E6*,E7,E1*I se-
quences (Fig. 4A). pCR31b-E79E was produced by
cloning of the 272-bp PCR product generated with
primers E7 59 and E1 39 on cDNA from CIN-612 9E raft
tissues, and it contains HPV31b E7,E1*I sequences.
pCR31b-E6E1.2b was made by cloning of the 2080-bp
PCR product generated with primers E6 59 and E1–2 39
on cDNA from CIN-612 9E tissues, and it contains
HPV31b E6*,E7,E1 sequences (Fig. 4C). Other cloning
was performed using standard techniques (Sambrook
et al., 1989). pCR31b-E6*E1 was made by digesting
pCR31b-E6E1.2b with HincII (HPV31 nt 1003; see Fig. 4)
and religating to a blunt-ended XbaI site in the vector
multiple cloning site. pBS-HPV31 was created by re-
moving the complete HPV31 genome from pBR-HPV31
and ligating it into the EcoRI site of pBS SK(1) (Strat-
agene, La Jolla, California). Double-stranded DNA se-
quencing was performed using the dideoxy method
with Sequenase Version 2.0 (U.S. Biochemical, Cleve-
land, Ohio). The sequencing products were separated
on 8% polyacrylamide–7 M urea sequencing gels.
Dried gels were exposed to Reflection film with inten-
sifying screens.
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Nuclease protection assays and primer extension
analyses
Radioactive antisense RNA probes were synthesized using
the MAXI script/RPA II kit (Ambion Inc., Austin, Texas) as
previously described (Ozbun and Meyers, 1996, 1997).
pCR31b-E1 was digested with StyI, which yielded a 416-nt
antisense probe predicted to protect 337 nt of the E1 ORF.
pCR31-E2 was digested with DraI, which gave a 339-nt
riboprobe expected to protect 260 nt specific to the E2
ORF. pCR31b-E79E was digested with AccI, giving rise to
a 248-nt riboprobe predicted to protect 169 nt of the E7,E1*I,E2
transcript and 132 nt corresponding to the E7,E1 region.
EcoRI digestion of pCR31b-E6*E1 yielded a 705-nt anti-
sense probe. This riboprobe was predicted to protect 682 nt
from the E6*,E7,E1 transcript, 592 nt from an unspliced
E6,E7,E1 transcript, 556 nt from the E6*,E7,E1^ region, and
465 nt of transcripts containing the region E6,E7,E1^.
Probes were purified and hybridizations were performed as
previously reported (Ozbun and Meyers, 1996, 1997). Sam-
ples were analyzed by electrophoresis through 5% poly-
acrylamide–7 M urea gels followed by autoradiography.
RNA Century standards were prepared as per the manu-
facturer’s recommendations (Ambion Inc.). The intensity of
protected fragments was measured by scanning laser den-
sitometry. Nuclease S1 and exonuclase VII protection as-
says and primer extension analyses were performed as
previously described (Ozbun and Meyers, 1997, 1998).
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